A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
ChromaDex flagship Tru Niagen (nicotinamide riboside) product now available in Showcase specialty retail stores in CanadaLOS ANGELES, April 15, 2019 -- ChromaDex Corp. (NASDAQ:CDXC) announced today the latest milestone in its global expansion strategy for TRU...
Data published in the Journal of American College of Cardiology shows that this novel form of vitamin B3 helps maintain mitochondrial function in an animal model by stimulating a cellular repair pathway; preliminary human data also support future testing of NR in...
World's leading expert on NAD metabolism to speak at #UpgradeXP2019 LOS ANGELES, April 03, 2019 -- ChromaDex Corp. (NASDAQ:CDXC) announced today its Chief Scientific Advisor, Dr. Charles Brenner, the world's foremost authority on NAD metabolism and discoverer of...
LOS ANGELES, March 11, 2019 -- ChromaDex Corp. (NASDAQ:CDXC) announced today that its Chief Executive Officer, Rob Fried, Chairman and Co-Founder, Frank Jaksch, and Chief Financial Officer, Kevin Farr, will present at the 31st annual ROTH Capital Partners Conference...
TRU NIAGEN® milestones to be highlighted at South by Southwest® SXSW® gathering of global professionals LOS ANGELES, March 08, 2019 -- ChromaDex Corp. (NASDAQ:CDXC) announced today it will feature its cellular health product, TRU NIAGEN®, at...
- Full Year 2018 Net Revenues Increased by 49% to $31.6 Million and Fourth Quarter 2018 Net Revenues Increased by 20% to $9.1 Million - Fourth Quarter 2018 Highlights vs. Fourth Quarter 2017 Entered into a global license and supply agreement with Nestlé Health...
LOS ANGELES, March 01, 2019 -- ChromaDex Corp. (NASDAQ:CDXC) announced today that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will present at the 39th Annual Cowen Heath Care Conference at the Boston Marriott Copley Place in...
LOS ANGELES, Feb. 28, 2019 -- ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Thurs., Mar. 7, 2019 at 4:30 p.m. Eastern time to discuss its financial results for the fourth quarter ended December 31, 2018. The financial results will be...
Landmark preclinical lactation study of unique form of vitamin B3 (nicotinamide riboside) showing remarkable results in rodents published in Cell Reports LOS ANGELES, Jan. 23, 2019 -- ChromaDex Corp. (NASDAQ:CDXC) today reported that results of a first-of-a-kind...
ChromaDex to move forward with patent infringement action, following unsuccessful challenge by Elysium Health during Inter Partes Review (IPR) LOS ANGELES, Jan. 22, 2019 -- ChromaDex Corp. (NASDAQ:CDXC) today reported the rejection of Elysium Health Inc.'s challenge...